鉴定口服生物可用氨酸衍生物作为潜在的AR抗原剂,向前列腺癌
Jinbiao Liao1, Jianing Liao1, Minkui Zhang1
1State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang 310058, China.
Journal of medicinal chemistry
|November 4, 2024
概括
一种新的化合物4a有效地准前列腺癌 (PCa) 中的雄激素受体 (AR),并克服耐药性. 这种口服药物显示出治疗晚期PCa的前景.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 雄激素受体 (AR) 信号驱动前列腺癌 (PCa) 的进展.
- 对AR抗剂的获得性耐药性限制了治疗疗效.
- 以前的库马林衍生物1显示出潜力,但具有较差的生物可用性.
研究的目的:
- 为了开发一种口服生物可用AR抗剂,克服耐药性.
- 优化库马林衍生物1以提高疗效和药理动力学.
主要方法:
- 库马林衍生物的基于结构的优化 1. 库马林衍生物的结构优化
- 在体外评估AR抗药活性和选择性.
- 在PCa异种移植模型中进行体内药理动力学研究和瘤生长抑制试验.
主要成果:
- 化合物4a表现出强大的AR抗作用 (IC50 = 0.051μM),与恩扎胺相似.
- 4a与现有药物相比,对关键AR突变 (ARF876L/T877A,ARW741C) 的疗效更高.
- 在体内研究显示,口服后有利的药理动力学 (F = 66.24%) 和显著的瘤生长抑制.
结论:
- 化合物4a是一种有前途的口服生物可用AR抗剂.
- 4a显示了克服前列腺癌抵抗机制的潜力.
- 进一步开发4a可以为高级PCa提供新的治疗选择.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
544
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
544
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
813
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
813
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


